Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Hepatitis C virus (HCV) incidence among men who have sex with men (MSM) living with HIV: results from the French Hospital Database on HIV (ANRS CO4-FHDH) cohort study, 2014 to 2017.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Corporate Authors:
      French Hospital Database on HIV (ANRS CO4-FHDH Cohort); The members of the ANRS CO4-FHDH cohort are acknowledged at the end of the article.
    • المصدر:
      Publisher: European Centre for Disease Prevention and Control (ECDC) Country of Publication: Sweden NLM ID: 100887452 Publication Model: Print Cited Medium: Internet ISSN: 1560-7917 (Electronic) Linking ISSN: 1025496X NLM ISO Abbreviation: Euro Surveill Subsets: MEDLINE
    • بيانات النشر:
      Publication: Stockholm, Sweden : European Centre for Disease Prevention and Control (ECDC)
      Original Publication: Saint-Maurice : Hôpital national de Saint-Maurice
    • الموضوع:
      HIV Infections*/drug therapy ; HIV Infections*/epidemiology ; Hepatitis C*/drug therapy ; Hepatitis C*/epidemiology ; Hepatitis C, Chronic* ; Sexual and Gender Minorities*; Antiviral Agents/therapeutic use ; Cohort Studies ; Hepacivirus ; Homosexuality, Male ; Hospitals ; Humans ; Incidence ; Male
    • نبذة مختصرة :
      BackgroundDespite the availability of highly effective direct-acting antivirals (DAAs) and the expected treatment as prevention (TasP) effect, transmission of hepatitis C virus (HCV) persists in men who have sex with men (MSM) who engage in high-risk sexual behaviours.AimWe aimed to estimate the incidence of primary HCV infection among MSM living with HIV in France when DAA was readily available.MethodsWe used data from a large French hospital cohort of persons living with HIV (ANRS CO4-FHDH) prospectively collected between 2014 and 2017. HCV incidence rates were calculated using person-time methods for HCV-negative MSM at inclusion who had serological follow-up from 1 January 2014 to 31 December 2017. Sensitivity analyses were performed by varying the main assumptions to assess their impact on the results.ResultsOf 14,273 MSM living with HIV who were initially HCV-seronegative, 330 acquired HCV during follow-up over 45,866 person-years (py), resulting in an overall estimated incidence rate of 0.72/100 py (95% CI: 0.65-0.80). HCV incidence significantly decreased from 0.98/100 py (95% CI: 0.81-1.19) in 2014 to 0.45/100 py (95% CI: 0.35-0.59) in 2017 (54% decrease; 95% CI: 36-67). This trend was confirmed by most of the sensitivity analyses.ConclusionThe primary incidence of HCV was halved for MSM living with HIV between 2014 and 2017. This decrease may be related to unrestricted DAA availability in France for individuals living with HIV. Further interventions, including risk reduction, are needed to reach HCV micro-elimination in MSM living with HIV.
    • References:
      AIDS. 2018 May 15;32(8):1077-1082. (PMID: 29438195)
      J Hepatol. 2020 May;72(5):855-864. (PMID: 31862485)
      Open Forum Infect Dis. 2020 Jan 12;7(1):ofaa019. (PMID: 32016128)
      AIDS Res Hum Retroviruses. 2007 Jun;23(6):769-76. (PMID: 17604539)
      Liver Int. 2018 Jun 30;:. (PMID: 29959866)
      J Hepatol. 2017 Aug;67(2):255-262. (PMID: 28412290)
      Clin Infect Dis. 2019 Nov 27;69(12):2127-2135. (PMID: 30810158)
      AIDS. 2010 Jul 31;24(12):1799-812. (PMID: 20601854)
      AIDS. 2018 Aug 24;32(13):1871-1879. (PMID: 29927787)
      AIDS. 2007 May 11;21(8):983-91. (PMID: 17457092)
      J Acquir Immune Defic Syndr. 2019 Sep 1;82(1):105-110. (PMID: 31169768)
      Open Forum Infect Dis. 2015 Aug 06;2(3):ofv115. (PMID: 26634219)
      HIV Med. 2016 Feb;17(2):83-8. (PMID: 26548563)
      Int J Epidemiol. 2014 Oct;43(5):1425-36. (PMID: 24550249)
      Clin Microbiol Infect. 2020 Jun;26(6):785.e1-785.e4. (PMID: 32035235)
      Int J Antimicrob Agents. 2020 Jul;56(1):105527. (PMID: 30145247)
      AIDS. 2020 Jan 1;34(1):47-52. (PMID: 31789889)
      PLoS One. 2011;6(12):e29322. (PMID: 22216248)
      AIDS. 2015 Nov;29(17):2335-45. (PMID: 26258525)
      AIDS. 2008 Oct 1;22(15):1979-91. (PMID: 18784461)
      Gut. 2020 Oct 27;:. (PMID: 33109688)
      AIDS. 2009 Jul 31;23(12):F1-7. (PMID: 19542864)
      AIDS. 2011 May 15;25(8):1083-91. (PMID: 21537114)
      Hepatology. 2018 Mar;67(3):847-857. (PMID: 29108121)
      Gastroenterology. 2009 May;136(5):1609-17. (PMID: 19422083)
      PLoS One. 2019 Mar 13;14(3):e0213526. (PMID: 30865722)
      Clin Infect Dis. 2018 Apr 17;66(9):1360-1365. (PMID: 29186320)
      Clin Infect Dis. 2021 Jan 27;72(2):233-238. (PMID: 32211763)
    • Contributed Indexing:
      Keywords: ANRS CO4-FHDH; DAA; HCV incidence rate; HIV; MSM; cohort study
    • الرقم المعرف:
      0 (Antiviral Agents)
    • الموضوع:
      Date Created: 20210924 Date Completed: 20210927 Latest Revision: 20220915
    • الموضوع:
      20231215
    • الرقم المعرف:
      PMC8462035
    • الرقم المعرف:
      10.2807/1560-7917.ES.2021.26.38.2001321
    • الرقم المعرف:
      34558403